
Qlife Q2 2023 - Cost reductions completed

Qlife has restructured its operations, reducing its workforce considerably and terminating its leasing contract, so the fixed costs will be much lower going forward. It will focus on co-development in medical research and sales of CRP tests with partners. The financial situation is still strained, but the company has cash to continue operations during this year.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Qlife Q2 2023 - Cost reductions completed